Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-1.46%
Variazione Mensile
+26.17%
Variazione di 6 mesi
+5.06%
Variazione Annuale
+4.25%
Chiusura Precedente
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Volume
57
Mercati
Mercato Azionario Statunitense
Salute
CCCC
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
70.59 M
70.99 M
71.01 M
71.17 M
96.91 M
97.58 M
—
Valuation ratios
Enterprise value
342.71 M
200.06 M
62.32 M
23.62 M
156.34 M
111.77 M
354.05 M
Price to earnings ratio
-3.35
-2.37
-1.08
-0.9
-1.32
-1.5
-4.81
Price to sales ratio
11.28
7.02
2.8
2.93
5.25
—
—
Price to cash flow ratio
4.88
3.83
1.39
1.15
1.67
1.6
5.82
Price to book ratio
0.36
1.16
0.12
0.12
0.21
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.07
0.1
0.08
0.09
0.12
0.06
0.35
Return on equity %
0.1
0.16
0.13
0.15
0.21
0.08
0.57
Return on invested capital %
76.84
112.39
92.51
98.05
140.69
87
418.25
Gross margin %
100
100
100
100
100
100
400
Operating margin %
183.86
728.39
402.93
440.99
306.43
210.1
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
160.57
667.82
363.66
402.6
286.43
185.97
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.31
5.71
5.7
5.06
5.76
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.02
0.02
0.04
0.04
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.35
0.26
0.47
0.17
0.43
0.27
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
4.08
3.85
3.31
3.14
2.75
3.58
12.79
Net current asset value per share
3.92
3.72
3.28
3.16
2.85
3.11
12.41
Tangible book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Working capital per share
3.3
3.06
2.71
2.54
2.36
2.72
10.32
Book value per share
3.49
3.11
2.75
2.45
2.13
3.1
10.43
Notizie
Barclays alza il target su C4 Therapeutics per progressi negli studi
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen conferma rating Buy su azioni C4 Therapeutics
TD Cowen reiterates Buy rating on C4 Therapeutics stock
Gli EPS di C4 hanno battuto le aspettative per 0,11$, il fatturato supera le previsioni
C4 earnings beat by $0.11, revenue topped estimates
Brookline Capital alza il target su C4 Therapeutics per progressi negli studi
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics tratta il primo paziente nello studio di fase 2 sul mieloma
C4 Therapeutics doses first patient in phase 2 myeloma trial
Il direttore medico di C4 Therapeutics Reyno vende azioni per 22.200 dollari
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock